Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil.

ABSTRACT: Patients with metastatic colorectal cancer (mCRC) are surviving longer now than ever before, but mortality rates are still high and more effective therapies are clearly needed. For patients with disease that is refractory to fluoropyrimidines, oxaliplatin, irinotecan, and biologic agents targeting the vascular endothelial growth factor and epidermal growth factor receptor pathways, novel treatment options trifluridine/tipiracil (TAS-102) and regorafenib can be effective disease stabilizers. However, objective clinical responses are rare and toxicities are manageable but common. In order to tackle poor clinical responses to TAS-102, there is an ongoing effort to effectively combine this drug with other agents, particularly those targeting angiogenesis. Certain subpopulations appear to benef

SUBMITTER: Puthiamadathil JM 

PROVIDER: S-EPMC5635852 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature